Plus Therapeutics (FRA:XMP1) Total Current Assets: €15.59 Mil (As of Mar. 2026)


FRA:XMP1 Plus Therapeutics Inc FRA:XMP1
22 GF Score
Price €3.38
! 2 Warning Signs
View Full Analysis

What is Plus Therapeutics Total Current Assets?

Plus Therapeutics FRA:XMP1 -3.01% 22 Total Current Assets is €15.59 Mil as of Mar. 2026. GuruFocus rates FRA:XMP1 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Plus Therapeutics's total current assets for the quarter that ended in Mar. 2026 was €15.59 Mil.

Plus Therapeutics  (FRA:XMP1) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Plus Therapeutics's Liquidation Value for the quarter that ended in Mar. 2026 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=13.074-6.881+0.75 * 0+0.5 * 0
=6.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Plus Therapeutics Total Current Assets Related Terms

Plus Therapeutics Total Current Assets Historical Data

* Premium members only.

The historical data trend for Plus Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Plus Therapeutics Total Current Assets Chart

Plus Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.46 20.60 9.02 5.02 12.96

Plus Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.05 7.99 14.98 12.96 15.59
FRA:XMP1
22GF Score
Plus Therapeutics Inc FRA:XMP1
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Plus Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Plus Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=7.355+0.275+0+5.325
=12.96

Plus Therapeutics's Total Current Assets for the quarter that ended in Mar. 2026 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=13.074+1.168+0+1.352
=15.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of €15.59 Mil mean?
Plus Therapeutics (FRA:XMP1) has a Total Current Assets of €15.59 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Plus Therapeutics and its competitors.
Is Plus Therapeutics' Total Current Assets too high?
Plus Therapeutics' current Total Current Assets is €15.59 Mil. Overall, Plus Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Plus Therapeutics' Total Current Assets compare to GRCE and NNVC?
Plus Therapeutics' Total Current Assets of €15.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Plus Therapeutics and its competitors. Plus Therapeutics's current Total Current Assets is €15.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plus Therapeutics stock overvalued right now?
Plus Therapeutics (FRA:XMP1) has a current Total Current Assets of €15.59 Mil. The current Total Current Assets is €15.59 Mil. Plus Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Plus Therapeutics (FRA:XMP1), the current Total Current Assets is €15.59 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Plus Therapeutics Business Description

Other Exchanges PSTV:USA
Address 6420 Levit Green Boulevard, Suite 210, Houston, TX, USA, 77021
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
22GF Score

Get the complete analysis for FRA:XMP1

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.38
Price